Zur Vorlage an die am 15. Juni 2022 stattfindende
5. ordentliche Hauptversammlung der
Marinomed Biotech AG

Erklärung gemäß § 87 Abs 2 AktG

Gemäß § 87 Abs 2 Aktiengesetz (AktG) hat jede für die Wahl in den Aufsichtsrat vorgeschlagene Person der Hauptversammlung ihre fachliche Qualifikation, ihre beruflichen oder vergleichbaren Funktionen sowie alle Umstände darzulegen, die die Besorgnis einer Befangenheit begründen könnten.

Zur Darlegung meiner fachlichen Qualifikation sowie meiner beruflichen oder vergleichbaren Funktionen verweise ich auf meinen angeschlossenen Lebenslauf.

Ich verfüge damit über die fachliche Qualifikation, die für die Tätigkeit des Aufsichtsrats der Marinomed Biotech AG erforderlich ist.

Weiters erkläre ich hiermit, dass

1. ich sämtliche Umstände im Zusammenhang mit § 87 Abs 2 AktG offen gelegt habe und nach meiner Beurteilung keine Umstände vorhanden sind, die die Besorgnis einer Befangenheit begründen könnten,
2. ich zu keiner gerichtlich strafbaren Handlung rechtskräftig verurteilt worden bin, insbesondere zu keiner solchen die gem § 87 Abs 2a S 3 AktG meine berufliche Zuverlässigkeit in Frage stellt,
3. keine Bestellungshindernisse im Sinne von § 86 Abs 2, insbesondere des § 86 Abs 2 Z 1 iVm § 86 Abs 3 AktG (Überschreiten der gesetzlichen Höchstzahl von Aufsichtsratsmandaten) und § 86 Abs 4 AktG bestehen,
4. ich keine Organfunktionen in anderen Gesellschaften wahrnehme, die zur Marinomed Biotech AG in Wettbewerb stehen, und
5. ich in keiner geschäftlichen oder persönlichen Beziehung zur Marinomed Biotech AG oder deren Vorstand stehe, die einen materiellen Interessenskonflikt begründet und daher geeignet ist, mein Verhalten als Mitglied des Aufsichtsrates zu beeinflussen.

Wien 22.05.22
Ort, Datum

Beilage:
Lebenslauf

unbeglaubigte Unterschrift

Personal

Nachreihengasse 8/9, A-1170 Wien/ +436767652457 / elisabeth@lackner.us

Summary

Entrepreneur and experienced well- networked pharmaceutical and biotechnology executive with 20+ years of experience combining growth, business strategy & innovation, marketing, business development and international expansion, regulatory and operations in life science with full P&L responsibility (10+ years CEO).
Engaging leader, strategist with the focus on creating value, entrepreneurial mind-set, results – driven, high integrity, cultural agility combined with extensive experience in leading multicultural teams.
Member of boards. Respected consultant and speaker in the industry.

Professional Experience

02.2020- Present **Member of Supervisory / Advisory Boards (PE and Life science)**

08.2021- Present **Managing Director Vineta (Family Office)** Vienna

Managing Director and Founder Xellient (Consultancy Arm of Vineta)
Vineta is a family office with focus on long term investments in Life science

- Responsible for planning the investment process in Life science / Healthcare / Medtech; Work closely with (portfolio) companies on a board level as well as operational level
- Life science / Healthcare / Medtech; Strategy consulting; Business development consulting; Operational consulting

09.2020- Present **General Manger of Trade D&A Pharma** Paris / Vienna (part- time)
D&A Pharma is a French pharmaceutical company specialized in the development of innovative and patented treatments of addictions.

- Planning and implementing operational and growth strategy

06.2016- 07.2021

CEO GBA Group Pharma / Munich / Vienna/ Saarbrucken / Neu - Ulm / Kiel
Qualified Person
Co- managing director GBA /Hamburg
GBA is laboratory and service provider with core competencies in environmental, food and pharmaceutical services.

- P&L responsibility (Pharma division 50 mEUR sales p.a; 450 employees; GBA 140mEUR sales p.a. 1200 employees)
- Set up of new GBA Group Pharma Division that led to a 400 % growth in 4 years
- Restructured and relocated existing laboratory sites that led to a significant growth in sales and EBIT
- Developed and implemented a global strategy for GBA Group Pharma
- Led the M&A strategy, Due Diligences process and integration
- Set up of global functions, site functions, reporting structures including finance, operations, quality, IT, logistics and business development as well as marketing
- Created and implemented the organization's vision, mission and overall direction
- Responsible for set up, maintenance and growth of international business development, business relations and international cooperation's in US, Europe and Asia Pacific region
- Represented the organization globally
- Direct report into board and PE

02.2010- 07.2021

CEO ABF Pharmaceutical Services GmbH
Qualified Person

ABF is an international CMO (Contract Manufacturing Organisation) for clinical trial supply

- P&L responsibility (10 mEUR sales p.a; 30 employees)
- Developed and implemented the overall international growth strategy that led to a 600 % growth in 6 years.
- Created and implemented the organization's vision, mission, and overall direction.
- Represented the organization globally. Implemented and maintained very successful business development
- Qualified Person for EU Batch Releases fulfilling the requirements specified in article 13.3 and undertaking the duties outlined in Annex 13.
- Successfully sold ABF to GBA 2016. Prepared , conducted and closed entire M&A process

04.2008- 01.2010 **Consultant** for pharmaceutical industry and biotechnology companies

- Drug development / R&D. Design and management of clinical program. Study planning, placement and monitoring. Strategic and operational input for clinical development

11.2005 -02.2012 **Roche Austria GmbH, Vienna** / Head of Manufacturing Roche Austria GmbH
Roche Austria GmbH, Vienna / Medical Manager Transplantation and HIV

- Supervised clinical trials. First contact person for marketing and sales for medical requests. Trained marketing and sales. Developed and maintained contacts with KOLs. Cooperation with Regulatory and other departments of the company

08.2003-11.2005 **Assign Clinical Research GmbH, Vienna, Austria, CEE/** Project Leader responsible for CEE; Manager of international Clinical Trials (CT)

- Management and set up of clinical trial team in CEE. Ensured the conduct of CT within timelines and budget as well as observed legal and regulatory standards in the conduct of CT. Developed and maintained contacts with national and international KOL in CEE. Organized and cooperated in the selection process of CROs and freelancers as well as contract negotiations in CEE. CRA.

02.2003-08.2003 **Assign Clinical Research GmbH / SKM /** Wiesbaden, Germany**;** Project Leader and Manager of international Clinical Trials (CT)

- Ensured the conduct of CT within timelines and budget as well as full legal and regulatory responsibility for standards in the conduct of CT. CRA

02.2001-01.2003 **Pharmacia, Milan, Italy /** Researcher in the department of Pharmacology/Oncology (Discover Research Oncology and R&D)

Languages: English (fluent), German (native), Italian (Intermediate), French (basic)

Education Ph.D; Institute for Cancer Research; University of Vienna; Diploma in Pharmacy (with distinction) University of Vienna /Centre R&D en Horticultural;Saint-Jean-sur Richelieu, Canada; Post graduate education “Tumorbiology